Literature DB >> 10742099

Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation.

R J Gibbons1, T L McDowell, S Raman, D M O'Rourke, D Garrick, H Ayyub, D R Higgs.   

Abstract

A goal of molecular genetics is to understand the relationship between basic nuclear processes, epigenetic changes and the numerous proteins that orchestrate these effects. One such protein, ATRX, contains a highly conserved plant homeodomain (PHD)-like domain, present in many chromatin-associated proteins, and a carboxy-terminal domain which identifies it as a member of the SNF2 family of helicase/ATPases. Mutations in ATRX give rise to characteristic developmental abnormalities including severe mental retardation, facial dysmorphism, urogenital abnormalities and alpha-thalassaemia. This circumstantial evidence suggests that ATRX may act as a transcriptional regulator through an effect on chromatin. We have recently shown that ATRX is localized to pericentromeric heterochromatin during interphase and mitosis, suggesting that ATRX might exert other chromatin-mediated effects in the nucleus. Moreover, at metaphase, some ATRX is localized at or close to the ribosomal DNA (rDNA) arrays on the short arms of human acrocentric chromosomes. Here we show that mutations in ATRX give rise to changes in the pattern of methylation of several highly repeated sequences including the rDNA arrays, a Y-specific satellite and subtelomeric repeats. Our findings provide a potential link between the processes of chromatin remodelling, DNA methylation and gene expression in mammalian development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10742099     DOI: 10.1038/74191

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  152 in total

Review 1.  Chromatin modification and disease.

Authors:  C A Johnson
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

2.  Lsh, a member of the SNF2 family, is required for genome-wide methylation.

Authors:  K Dennis; T Fan; T Geiman; Q Yan; K Muegge
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

Review 3.  Above and within the genome: epigenetics past and present.

Authors:  F D Urnov; A P Wolffe
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

Review 4.  Genetic effects on human cognition: lessons from the study of mental retardation syndromes.

Authors:  P Nokelainen; J Flint
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

5.  Identification of a conserved erythroid specific domain of histone acetylation across the alpha-globin gene cluster.

Authors:  E Anguita; C A Johnson; W G Wood; B M Turner; D R Higgs
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  mediator of paramutation1 is required for establishment and maintenance of paramutation at multiple maize loci.

Authors:  J E Dorweiler; C C Carey; K M Kubo; J B Hollick; J L Kermicle; V L Chandler
Journal:  Plant Cell       Date:  2000-11       Impact factor: 11.277

7.  RNA-directed DNA methylation in Arabidopsis.

Authors:  Werner Aufsatz; M Florian Mette; Johannes van der Winden; Antonius J M Matzke; Marjori Matzke
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

Review 8.  Induction and maintenance of nonsymmetrical DNA methylation in Neurospora.

Authors:  Eric U Selker; Michael Freitag; Gregory O Kothe; Brian S Margolin; Michael R Rountree; C David Allis; Hisashi Tamaru
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-20       Impact factor: 11.205

Review 9.  The control of expression of the alpha-globin gene cluster.

Authors:  Hua-bing Zhang; De-Pei Liu; Chih-Chuan Liang
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

10.  Lsh, a modulator of CpG methylation, is crucial for normal histone methylation.

Authors:  Qingsheng Yan; Jiaqiang Huang; Tao Fan; Heming Zhu; Kathrin Muegge
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.